首页> 外文OA文献 >Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial
【2h】

Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial

机译:灌注-CT引导静脉溶栓患者未知发病中风:随机,双盲,安慰剂控制,试验可行性试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

INTRODUCTION: Patients with unknown stroke onset are generally excluded from acute recanalisation treatments. We designed a pilot study to assess feasibility of a trial of perfusion computed tomography (PCT)-guided thrombolysis in patients with ischemic tissue at risk of infarction and unknown stroke onset.METHODS: Patients with a supratentorial stroke of unknown onset in the middle cerebral artery territory and significant volume of at-risk tissue on PCT were randomized to intravenous thrombolysis with alteplase (0.9 mg/kg) or placebo. Feasibility endpoints were randomization and blinded treatment of patients within 2 h after hospital arrival, and the correct application (estimation) of the perfusion imaging criteria.RESULTS: At baseline, there was a trend towards older age [69.5 (57-78) vs. 49 (44-78) years] in the thrombolysis group (n = 6) compared to placebo (n = 6). Regarding feasibility, hospital arrival to treatment delay was above the allowed 2 h in three patients (25%). There were two protocol violations (17%) regarding PCT, both underestimating the predicted infarct in patients randomized in the placebo group. No symptomatic hemorrhage or death occurred during the first 7 days. Three of the four (75%) and one of the five (20%) patients were recanalized in the thrombolysis and placebo group respectively. The volume of non-infarcted at-risk tissue was 84 (44-206) cm(3) in the treatment arm and 29 (8-105) cm(3) in the placebo arm.CONCLUSIONS: This pilot study shows that a randomized PCT-guided thrombolysis trial in patients with stroke of unknown onset may be feasible if issues such as treatment delays and reliable identification of tissue at risk of infarction tissue are resolved. Safety and efficiency of such an approach need to be established.
机译:简介:患有未知卒中症的患者通常被排除在急性重新分析治疗之外。我们设计了一个试点研究,以评估灌注计算断层扫描(PCT) - 导溶解的可行性,梗死组织患者梗死和未知的中风onset.methods:中间脑动脉未知发病患者的患者PCT的境内和大量的风险组织被随机分为静脉溶栓(0.9mg / kg)或安慰剂。在医院到达后2小时内的可行性终点是随机化和盲目治疗患者的患者,以及灌注成像标准的正确应用(估计)。结果:在基线时,年龄较大的趋势[69.5(57-78)与49(44-78)年]与安慰剂(n = 6)相比,溶栓组(n = 6)。关于可行性,医院到达治疗延迟高于3名患者的2小时(25%)。关于PCT有两种违规行为(17%),两者都在低估了安慰剂组随机化的患者中预测的梗塞。在前7天内没有发生症状出血或死亡。四种(75%)中的三种和五种(20%)患者中的三种分别在溶栓和安慰剂组中重新分别进行。治疗臂中的非梗死风险组织的体积为84(44-206)厘米(3),安慰剂ARM的29(8-105)cm(3)。结论:该试点研究表明随机化如果治疗延迟等问题诸如梗死组织风险的组织诸如治疗延迟和可靠的组织的问题,则患有未知发病患者的PCT引导的溶栓试验可能是可行的。需要建立这种方法的安全性和效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号